Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity
The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.
1. A method of decreasing IFN-λ1 gene activity in an airway epithelial cell, comprising the steps of:
i) providing an airway epithelial cell in need of decreasing IFN-λ1 gene activity, said airway epithelial cell is viral-stimulated; and
ii) exposing said airway epithelial cell to a siRNA oligonucleotide targeted against GATA1 transcriptional factor, thereby decreasing IFN-λ1 gene activity in said airway epithelial cell, as indicated by a decrease in IFN-λ1 protein expression,
wherein said GATA1 mRNA has a nucleotide sequence set for in Accession No: NM_002049.
2. The method of claim 1 , wherein said siRNA oligonucleotide is at least one siRNA oligonucleotide selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 and SEQ ID NO: 55.
3. The method of claim 1 , wherein said decrease IFN-λ1 protein expression is measured by a decrease in IFN-λ1 protein secretion.
4. The method of claim 1 , wherein said decreased IFN-λ1 protein expression is measured by an ELISA.
5. The method of claim 1 , wherein said airway epithelial cell is a human airway epithelial cell.
6. The method of claim 1 , wherein said siRNA oligonucleotide is a modified siRNA oligonucleotide.